- Email: [email protected]
NanoVelcro Technology for the Capture and Molecular Analysis of Pancreatic Circulating Tumor Cells
502
ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS
8.4. Inhibitor of Nuclear Factor kB Activation Enhances the Antitumor Effect of Radiation Therapy for Pancreatic Cancer. Y. Shirai,1 H. Shiba,1 T. Uwagawa,1 R. Iwase,1 K. Haruki,1 Y. Fujiwara,1 K. Furukawa,1 T. Iida,1 Y. Futagawa,1 T. Misawa,1 T. Ohashi,1 K. Yanaga1; 1The Jikei University School Of Medicine - Surgery, Tokyo, TOKYO, Japan 8.5. Predictors of Mortality in Patients Undergoing Palliative Bypass for Pancreatic Malignancy. E. K. Bartlett,1 H. Wachtel,1 G. C. Karakousis,1 D. L. Fraker,1 J. A. Drebin,1 R. R. Kelz,1 R. E. Roses1; 1Hospital Of The University Of Pennsylvania - Department Of Surgery, Philadelphia, PA, USA 8.6. Laparoscopic Whipple: Feasibility and Outcomes. M. A. Makary,1 H. G. Lyu,1 M. A. Cooper,1 K. Hirose,1 J. L. Cameron,1 B. H. Edil2; 1Johns Hopkins University School Of Medicine, Baltimore, MD, USA; 2University Of Colorado Denver, Aurora, CO, USA 8.7. An Assessment of Jejunostomy Tube Placement in Patients Undergoing Pancreaticoduodenectomy for Adenocarcinoma: Routine Placement is not Justified. B. E. Johnson,1 A. R. Cyr,1 A. M. Button,1 H. Hoshi,1 J. R. Howe,1 J. J. Mezhir1; 1University Of Iowa - Surgical Oncology, Iowa City, IA, USA 8.8. DNA Methylation Regulates Expression of the RON Tyrosine Kinase Receptor in Pancreatic Cancer. J. Chakedis,1 R. French,1 D. Jaquish,1 E. Mose,1 H. Howard,1 A. M. Lowy1; 1 University Of California - San Diego - Division Of Surgical Oncology, Department Of Surgery, San Diego, CA, USA 8.9. Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. C. J. Clark,1 R. W. Randle,1 K. R. Swett,2 A. N. Doud,1 P. Shen,1 J. H. Stewart,1 E. A. Levine,1 K. I. Votanopoulos1; 1 Wake Forest University School Of Medicine - General Surgery, Winston-Salem, NC, USA; 2Wake Forest University School Of Medicine - Biostatistics, Winston-Salem, NC, USA 8.10. Immune Response Plays an Important Role in KRASG12D Induced Tumorigenesis in PDX1 Expressing Cells in Pancreas. J. Yu,1 J. Wu,1 S. Liu,1 G. Zhou,1 R. Sanchez,1 D. Dawson,1 J. Nemunaitis,2 F. C. Brunicardi1; 1 University Of California - Los Angeles - Surgery, Los Angeles, CA, USA; 2Mary Crowley Cancer Research Center, Dallas, TX, USA 8.11. Highly Metastatic Chemoresistant Stem-like Cells Selected by Serial Passage of Human Pancreatic Cancer Cells in Orthotopic Mouse Models. C. A. Metildi,1 S. Kaushal,1 R. M. Hoffman,1,2 M. Bouvet1; 1University Of California - San Diego - Surgery, San Diego, CA, USA; 2 AntiCancer, Inc., San Diego, CA, USA 8.12. Optimization of Chimeric Anti-CEA Antibody Labeling with Visable and Near-Infrared Dyes for High Resolution Imaging of Pancreatic Cancer in
Orthotopic Nude Mouse Models. A. A. Maawy,1 S. Kaushal,1 G. A. Luiken,3 R. M. Hoffman,1,2 M. Bouvet1; 1 University Of California - San Diego, San Diego, CA, USA; 2 AntiCancer, Inc., San Diego, CA, USA; 3OncoFluor, Inc., San Diego, CA, USA 8.13. Muc1 Promoter Driven Diptheria Toxin A as a Novel Therapy for Pancreatic Cancer. R. M. Tholey,1 R. A. Burkhart,1 J. A. Cozzitorto,1 C. J. Yeo,1 J. A. Sawicki,2 J. R. Brody,1 J. M. Winter1; 1Thomas Jefferson University Surgery, Philadelphia, PA, USA; 2Lankenau Institute For Medical Research, Wynnewood, PA, USA
8.14. Sensitivity of Alternative Analysis of ERCP Samples: A 10-Year Review of the Literature. A. Burnett,1 J. Bailey,1 S. Ahlawat,1 R. Chokshi1; 1Rutgers University - Department Of Surgery, Newark, NJ, USA 8.15. The Impact of Cytotoxic Chemotherapy on Pancreatic Stellate Cells. P. A. Toste,1 B. E. Kadera,1 A. H. Nguyen,1 M. Duong,1 N. Wu,1 L. Li,1 T. R. Donahue1; 1University Of California - Los Angeles - General Surgery, Los Angeles, CA, USA
8.16. Sarcopenia Predicts Operative Complications Following Pancreatectomy for Adenocarcinoma. S. Joglekar,1 A. Asghar,1 B. E. Johnson,1 S. Bell,1 A. Button,1 A. Palakodeti,1 M. Rajput,1 J. R. Howe,1 J. J. Mezhir1; 1 University Of Iowa - Surgical Oncology, Iowa City, IA, USA
8.18. Ascites Is A Risk Factor for Increased Postoperative Morbidity and Mortality in Patients That Undergo Pancreatic Necrosectomy for Acute Pancreatic Necrosis. N. Agee,1 S. De La Fuente,1,2 J. Arnoletti,1,2 S. Eubanks,1 D. G. Blazer,3 T. Pappas,3 J. Scarborough3; 1Florida Hospital Department Of Surgery, Orlando, FL, USA; 2University Of Central Florida - Department Of Surgery, Orlando, FL, USA; 3 Duke University Medical Center - Department of Surgery, Durham, NC, USA
8.19. NanoVelcro Technology for the Capture and Molecular Analysis of Pancreatic Circulating Tumor Cells. J. S. Ankeny,1,3 S. Hou,2,3,4 M. Lin,2,3,4 H. OuYang,2,3,4 M. Song,2,3,4 M. M. Rochefort,1,3 M. D. Girgis,1,3 H. R. Tseng,2,3,4 J. S. Tomlinson1,3,4; 1University Of California - Los Angeles Surgery, Los Angeles, CA, USA; 2University Of California Los Angeles - Molecular And Medical Pharmacology, Los Angeles, CA, USA; 3California NanoSystems Institute, Los Angeles, CA, USA; 4Crump Institute For Molecular Imaging, Los Angeles, CA, USA
8.20. Pancreatic Neuroendocrine Tumors (PNETs) – Can a 2 cm Cutoff be Used to Predict Adverse Outcomes? B. C. James,1 E. Kenning,1 N. H. Bhayani,1 E. T. Kimchi,1 K. F. Staveley-O’Carroll,1 B. D. Saunders,1 N. J. Gusani1; 1 Penn State University College Of Medicine - Program For Liver, Pancreas, & Foregut Tumors, Hershey, PA, USA
ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS
8.4. Inhibitor of Nuclear Factor kB Activation Enhances the Antitumor Effect of Radiation Therapy for Pancreatic Cancer. Y. Shirai,1 H. Shiba,1 T. Uwagawa,1 R. Iwase,1 K. Haruki,1 Y. Fujiwara,1 K. Furukawa,1 T. Iida,1 Y. Futagawa,1 T. Misawa,1 T. Ohashi,1 K. Yanaga1; 1The Jikei University School Of Medicine - Surgery, Tokyo, TOKYO, Japan 8.5. Predictors of Mortality in Patients Undergoing Palliative Bypass for Pancreatic Malignancy. E. K. Bartlett,1 H. Wachtel,1 G. C. Karakousis,1 D. L. Fraker,1 J. A. Drebin,1 R. R. Kelz,1 R. E. Roses1; 1Hospital Of The University Of Pennsylvania - Department Of Surgery, Philadelphia, PA, USA 8.6. Laparoscopic Whipple: Feasibility and Outcomes. M. A. Makary,1 H. G. Lyu,1 M. A. Cooper,1 K. Hirose,1 J. L. Cameron,1 B. H. Edil2; 1Johns Hopkins University School Of Medicine, Baltimore, MD, USA; 2University Of Colorado Denver, Aurora, CO, USA 8.7. An Assessment of Jejunostomy Tube Placement in Patients Undergoing Pancreaticoduodenectomy for Adenocarcinoma: Routine Placement is not Justified. B. E. Johnson,1 A. R. Cyr,1 A. M. Button,1 H. Hoshi,1 J. R. Howe,1 J. J. Mezhir1; 1University Of Iowa - Surgical Oncology, Iowa City, IA, USA 8.8. DNA Methylation Regulates Expression of the RON Tyrosine Kinase Receptor in Pancreatic Cancer. J. Chakedis,1 R. French,1 D. Jaquish,1 E. Mose,1 H. Howard,1 A. M. Lowy1; 1 University Of California - San Diego - Division Of Surgical Oncology, Department Of Surgery, San Diego, CA, USA 8.9. Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. C. J. Clark,1 R. W. Randle,1 K. R. Swett,2 A. N. Doud,1 P. Shen,1 J. H. Stewart,1 E. A. Levine,1 K. I. Votanopoulos1; 1 Wake Forest University School Of Medicine - General Surgery, Winston-Salem, NC, USA; 2Wake Forest University School Of Medicine - Biostatistics, Winston-Salem, NC, USA 8.10. Immune Response Plays an Important Role in KRASG12D Induced Tumorigenesis in PDX1 Expressing Cells in Pancreas. J. Yu,1 J. Wu,1 S. Liu,1 G. Zhou,1 R. Sanchez,1 D. Dawson,1 J. Nemunaitis,2 F. C. Brunicardi1; 1 University Of California - Los Angeles - Surgery, Los Angeles, CA, USA; 2Mary Crowley Cancer Research Center, Dallas, TX, USA 8.11. Highly Metastatic Chemoresistant Stem-like Cells Selected by Serial Passage of Human Pancreatic Cancer Cells in Orthotopic Mouse Models. C. A. Metildi,1 S. Kaushal,1 R. M. Hoffman,1,2 M. Bouvet1; 1University Of California - San Diego - Surgery, San Diego, CA, USA; 2 AntiCancer, Inc., San Diego, CA, USA 8.12. Optimization of Chimeric Anti-CEA Antibody Labeling with Visable and Near-Infrared Dyes for High Resolution Imaging of Pancreatic Cancer in
Orthotopic Nude Mouse Models. A. A. Maawy,1 S. Kaushal,1 G. A. Luiken,3 R. M. Hoffman,1,2 M. Bouvet1; 1 University Of California - San Diego, San Diego, CA, USA; 2 AntiCancer, Inc., San Diego, CA, USA; 3OncoFluor, Inc., San Diego, CA, USA 8.13. Muc1 Promoter Driven Diptheria Toxin A as a Novel Therapy for Pancreatic Cancer. R. M. Tholey,1 R. A. Burkhart,1 J. A. Cozzitorto,1 C. J. Yeo,1 J. A. Sawicki,2 J. R. Brody,1 J. M. Winter1; 1Thomas Jefferson University Surgery, Philadelphia, PA, USA; 2Lankenau Institute For Medical Research, Wynnewood, PA, USA
8.14. Sensitivity of Alternative Analysis of ERCP Samples: A 10-Year Review of the Literature. A. Burnett,1 J. Bailey,1 S. Ahlawat,1 R. Chokshi1; 1Rutgers University - Department Of Surgery, Newark, NJ, USA 8.15. The Impact of Cytotoxic Chemotherapy on Pancreatic Stellate Cells. P. A. Toste,1 B. E. Kadera,1 A. H. Nguyen,1 M. Duong,1 N. Wu,1 L. Li,1 T. R. Donahue1; 1University Of California - Los Angeles - General Surgery, Los Angeles, CA, USA
8.16. Sarcopenia Predicts Operative Complications Following Pancreatectomy for Adenocarcinoma. S. Joglekar,1 A. Asghar,1 B. E. Johnson,1 S. Bell,1 A. Button,1 A. Palakodeti,1 M. Rajput,1 J. R. Howe,1 J. J. Mezhir1; 1 University Of Iowa - Surgical Oncology, Iowa City, IA, USA
8.18. Ascites Is A Risk Factor for Increased Postoperative Morbidity and Mortality in Patients That Undergo Pancreatic Necrosectomy for Acute Pancreatic Necrosis. N. Agee,1 S. De La Fuente,1,2 J. Arnoletti,1,2 S. Eubanks,1 D. G. Blazer,3 T. Pappas,3 J. Scarborough3; 1Florida Hospital Department Of Surgery, Orlando, FL, USA; 2University Of Central Florida - Department Of Surgery, Orlando, FL, USA; 3 Duke University Medical Center - Department of Surgery, Durham, NC, USA
8.19. NanoVelcro Technology for the Capture and Molecular Analysis of Pancreatic Circulating Tumor Cells. J. S. Ankeny,1,3 S. Hou,2,3,4 M. Lin,2,3,4 H. OuYang,2,3,4 M. Song,2,3,4 M. M. Rochefort,1,3 M. D. Girgis,1,3 H. R. Tseng,2,3,4 J. S. Tomlinson1,3,4; 1University Of California - Los Angeles Surgery, Los Angeles, CA, USA; 2University Of California Los Angeles - Molecular And Medical Pharmacology, Los Angeles, CA, USA; 3California NanoSystems Institute, Los Angeles, CA, USA; 4Crump Institute For Molecular Imaging, Los Angeles, CA, USA
8.20. Pancreatic Neuroendocrine Tumors (PNETs) – Can a 2 cm Cutoff be Used to Predict Adverse Outcomes? B. C. James,1 E. Kenning,1 N. H. Bhayani,1 E. T. Kimchi,1 K. F. Staveley-O’Carroll,1 B. D. Saunders,1 N. J. Gusani1; 1 Penn State University College Of Medicine - Program For Liver, Pancreas, & Foregut Tumors, Hershey, PA, USA